Published 5 days ago • loading... • Updated 4 days ago

European, American, Chinese labs... The Global Battle for Obesity Treatments Is Raging

DECRYPTAGE - This very promising market, but today in the hands of the duopole Novo Nordisk-Eli Lilly, sharpens appetites. Players from all over the world are starting the race.

2 Articles

Le Figaro

Lean Right

European, American, Chinese labs... The Global Battle for Obesity Treatments Is Raging

DECRYPTAGE - This very promising market, but today in the hands of the duopole Novo Nordisk-Eli Lilly, sharpens appetites. Players from all over the world are starting the race.

5 days ago·Paris, France

Read Full Article

borsen.dk

Mike Doustdar: The Weight Loss Battle Against Lilly Will Not Be a “Zero-Sum Game”

Mike Doustdar stresses that investors are underestimating the demand for multiple obesity treatment options

4 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left0Leaning Right1Center0Last Updated4 days agoBias Distribution

100% Right

Bias Distribution

100% of the sources lean Right

100% Right

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Le Figaro broke the news in Paris, France 5 days ago on Thursday, August 13, 2026.

Sources are mostly out of (0)

European, American, Chinese labs... The Global Battle for Obesity Treatments Is Raging

2 Articles

2 Articles

European, American, Chinese labs... The Global Battle for Obesity Treatments Is Raging

Mike Doustdar: The Weight Loss Battle Against Lilly Will Not Be a “Zero-Sum Game”

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Nestle Looks to Develop New Products to Serve Users of Weight-Loss Drugs

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly: 'Competition Has to Be Fair'

The $109 Billion Fund Behind Novo Says US Renewables Are Now 'Much More Attractive'

Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles

Retatrutide, a Superpowerful Obesity Drug, Is Not Yet FDA-Approved — but Knockoffs Abound

Similar News Topics

Similar News Topics

More stories like this

Nestle Looks to Develop New Products to Serve Users of Weight-Loss Drugs

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly: 'Competition Has to Be Fair'

The $109 Billion Fund Behind Novo Says US Renewables Are Now 'Much More Attractive'

Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles

Retatrutide, a Superpowerful Obesity Drug, Is Not Yet FDA-Approved — but Knockoffs Abound

European, American, Chinese labs... The Global Battle for Obesity Treatments Is Raging

2 Articles

2 Articles

Translate IconEuropean, American, Chinese labs... The Global Battle for Obesity Treatments Is Raging

Translate IconMike Doustdar: The Weight Loss Battle Against Lilly Will Not Be a “Zero-Sum Game”

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Nestle Looks to Develop New Products to Serve Users of Weight-Loss Drugs

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly: 'Competition Has to Be Fair'

The $109 Billion Fund Behind Novo Says US Renewables Are Now 'Much More Attractive'

Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles

Retatrutide, a Superpowerful Obesity Drug, Is Not Yet FDA-Approved — but Knockoffs Abound

Similar News Topics

Similar News Topics

More stories like this

Nestle Looks to Develop New Products to Serve Users of Weight-Loss Drugs

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

Novo Nordisk CEO Defends Lawsuit Against Eli Lilly: 'Competition Has to Be Fair'

The $109 Billion Fund Behind Novo Says US Renewables Are Now 'Much More Attractive'

Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles

Retatrutide, a Superpowerful Obesity Drug, Is Not Yet FDA-Approved — but Knockoffs Abound

European, American, Chinese labs... The Global Battle for Obesity Treatments Is Raging

Mike Doustdar: The Weight Loss Battle Against Lilly Will Not Be a “Zero-Sum Game”

Bias Distribution

Factuality